In a trial of 106 males, the researchers were able to distinguish cancer from benign hypertrophy with 67.4% sensitivity and 71.2% specificity using urinary calgranulin B. Muller et al., on the other hand, found no link between urine MRP‐14 and prostate cancer147 In patients with prostate cancer, urinary‐MSMB was lower than in individuals with benign prostatic diseases. Here, S100A9 is linked to prostate cancer.